- Home
- RGC vs STTK Comparison
RGC vs STTK Comparison
Compare RGC & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- STTK
- Stock Information
- Founded
- RGC 2014
- STTK 2016
- Country
- RGC Hong Kong
- STTK United States
- Employees
- RGC N/A
- STTK N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- STTK Health Care
- Exchange
- RGC Nasdaq
- STTK Nasdaq
- Market Cap
- RGC 38.6B
- STTK 37.6M
- IPO Year
- RGC 2021
- STTK 2020
- Fundamental
- Price
- RGC $14.66
- STTK $0.83
- Analyst Decision
- RGC
- STTK Hold
- Analyst Count
- RGC 0
- STTK 4
- Target Price
- RGC N/A
- STTK $3.00
- AVG Volume (30 Days)
- RGC 2.8M
- STTK 423.3K
- Earning Date
- RGC 06-30-2025
- STTK 07-31-2025
- Dividend Yield
- RGC N/A
- STTK N/A
- EPS Growth
- RGC N/A
- STTK N/A
- EPS
- RGC N/A
- STTK N/A
- Revenue
- RGC N/A
- STTK $4,606,000.00
- Revenue This Year
- RGC N/A
- STTK N/A
- Revenue Next Year
- RGC N/A
- STTK N/A
- P/E Ratio
- RGC N/A
- STTK N/A
- Revenue Growth
- RGC N/A
- STTK 69.65
- 52 Week Low
- RGC $0.08
- STTK $0.69
- 52 Week High
- RGC $83.60
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- RGC 45.32
- STTK 38.86
- Support Level
- RGC $9.39
- STTK $0.75
- Resistance Level
- RGC $30.00
- STTK $0.85
- Average True Range (ATR)
- RGC 6.44
- STTK 0.09
- MACD
- RGC -1.70
- STTK -0.01
- Stochastic Oscillator
- RGC 20.68
- STTK 9.59
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.